Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kay Washington

Showing results (351-360 of 368) with videos related to

Pageof 37
Sort By:
Cell|May 1, 2026
An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gutLuisella Spiga, Ryan T Fansler, Yifan Wu, et al.
Cancer Research|May 14, 2009
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagusZhe Jin, Yulan Cheng, Wen Gu, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
A Specialized Epithelial Cell Type Regulating Mucosal Immunity and Driving Human Crohn's DiseaseJia Li, Alan J Simmons, Sophie Chiron, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Esophageal cancerJaffer A Ajani, James S Barthel, Tanios Bekaii-Saab, et al.
The Journal of Clinical Investigation|February 17, 2026
Pathobiont-triggered induction of goblet cell response drives regional susceptibility to Inflammatory Bowel DiseasePaige N Spencer, Monica E Brown, Erin P Smith, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 23, 2010
Gastric cancerJaffer A Ajani, James S Barthel, Tanios Bekaii-Saab, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 9, 2011
Esophageal and esophagogastric junction cancersJaffer A Ajani, James S Barthel, David J Bentrem, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
Pathobiont-triggered induction of epithelial IDO1 drives regional susceptibility to Inflammatory Bowel DiseasePaige N Spencer, Jiawei Wang, Erin P Smith, et al.
Cancer Letters|May 23, 2026
EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecanSarah J Harmych, Neeraj Joshi, Hidenori Tanaka, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Gastric cancer, version 2.2013: featured updates to the NCCN GuidelinesJaffer A Ajani, David J Bentrem, Stephen Besh, et al.
Pageof 37

Showing results (351-360 of 368) with videos related to

Sort By:
Pageof 37
Cell|May 1, 2026
An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gutLuisella Spiga, Ryan T Fansler, Yifan Wu, et al.
Cancer Research|May 14, 2009
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagusZhe Jin, Yulan Cheng, Wen Gu, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
A Specialized Epithelial Cell Type Regulating Mucosal Immunity and Driving Human Crohn's DiseaseJia Li, Alan J Simmons, Sophie Chiron, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Esophageal cancerJaffer A Ajani, James S Barthel, Tanios Bekaii-Saab, et al.
The Journal of Clinical Investigation|February 17, 2026
Pathobiont-triggered induction of goblet cell response drives regional susceptibility to Inflammatory Bowel DiseasePaige N Spencer, Monica E Brown, Erin P Smith, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 23, 2010
Gastric cancerJaffer A Ajani, James S Barthel, Tanios Bekaii-Saab, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 9, 2011
Esophageal and esophagogastric junction cancersJaffer A Ajani, James S Barthel, David J Bentrem, et al.
Biorxiv : the Preprint Server for Biology|January 13, 2025
Pathobiont-triggered induction of epithelial IDO1 drives regional susceptibility to Inflammatory Bowel DiseasePaige N Spencer, Jiawei Wang, Erin P Smith, et al.
Cancer Letters|May 23, 2026
EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecanSarah J Harmych, Neeraj Joshi, Hidenori Tanaka, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Gastric cancer, version 2.2013: featured updates to the NCCN GuidelinesJaffer A Ajani, David J Bentrem, Stephen Besh, et al.
Pageof 37